Company profile · Biotech & medical
BioGend Therapeutics
博晟生醫股份有限公司 · 6733
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
BioGend Therapeutics develops drugs and medical devices focusing on orthopedic regeneration and severe infections.[1]
Its core products include RevoCart for one-time autologous cartilage repair and OIF as a next-generation bone graft product.[1]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$21m | +24.8% | -0.0% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$0m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | BioGend Therapeutics Co., Ltd. |
|---|---|
| Chinese name | 博晟生醫股份有限公司 |
| Stock code | 6733 (TPEx) |
| Industry | Biotech & medical |
| Founded | 07 Jul 2016 |
| Listed | 28 Jan 2021 |
| Paid-in capital | NT$1.3bn |
| Chairman | 陳德禮 |
| President | 陳德禮 |
| Headquarters | 4F, No.3-2, Yuang St.Nangang District Taipei City, Taiwan, R.O.C. |
| Website | https://www.biogend.com.tw/ |
| Official business description | 複合性醫材 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- RevoCart'愛膝康' 一次性自體軟骨修復 退化性關節炎膝蓋磨損及早治療!軟骨修復免換關節! 退化性關節炎及早治療，一次性軟骨修復免換人工關節，膝蓋痛小心軟骨磨損 · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list